JP6831372B2 - 架橋ピペリジン誘導体 - Google Patents

架橋ピペリジン誘導体 Download PDF

Info

Publication number
JP6831372B2
JP6831372B2 JP2018512604A JP2018512604A JP6831372B2 JP 6831372 B2 JP6831372 B2 JP 6831372B2 JP 2018512604 A JP2018512604 A JP 2018512604A JP 2018512604 A JP2018512604 A JP 2018512604A JP 6831372 B2 JP6831372 B2 JP 6831372B2
Authority
JP
Japan
Prior art keywords
triazolo
azabicyclo
octane
amine
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018512604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526410A5 (enExample
JP2018526410A (ja
Inventor
バウマン，カールハインツ
ガレイ，グイド
ヤーコップ−ルートネ，ローラント
リンベルク，アンニャ
ナイトハルト，ヴェルナー
ロドリゲス・サルミエント，ロサ・マリア
バルテルス，ビョルン
ラトニ，アサヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2018526410A publication Critical patent/JP2018526410A/ja
Publication of JP2018526410A5 publication Critical patent/JP2018526410A5/ja
Application granted granted Critical
Publication of JP6831372B2 publication Critical patent/JP6831372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018512604A 2015-09-09 2016-09-05 架橋ピペリジン誘導体 Active JP6831372B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15184480 2015-09-09
EP15184480.0 2015-09-09
PCT/EP2016/070800 WO2017042114A1 (en) 2015-09-09 2016-09-05 Bridged piperidine derivatives

Publications (3)

Publication Number Publication Date
JP2018526410A JP2018526410A (ja) 2018-09-13
JP2018526410A5 JP2018526410A5 (enExample) 2019-09-26
JP6831372B2 true JP6831372B2 (ja) 2021-02-17

Family

ID=54072754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018512604A Active JP6831372B2 (ja) 2015-09-09 2016-09-05 架橋ピペリジン誘導体

Country Status (7)

Country Link
US (1) US10604517B2 (enExample)
EP (1) EP3347363B1 (enExample)
JP (1) JP6831372B2 (enExample)
CN (1) CN107922437B (enExample)
AR (1) AR105965A1 (enExample)
TW (1) TWI716446B (enExample)
WO (1) WO2017042114A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6831372B2 (ja) 2015-09-09 2021-02-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 架橋ピペリジン誘導体
JP7012715B2 (ja) * 2016-06-27 2022-01-28 エフ．ホフマン－ラ ロシュ アーゲー γ－セクレターゼモジュレーターとしてのトリアゾロピリジン
CN109689653B (zh) 2016-09-09 2022-04-12 豪夫迈·罗氏有限公司 用于制备2-(6-硝基吡啶-3-基)-9H-二吡啶并[2，3-b；3’，4’-d]吡咯的方法
AR109829A1 (es) * 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
CN109476670B (zh) 2016-10-04 2022-06-28 豪夫迈·罗氏有限公司 二环杂芳基衍生物
EP3535266B1 (en) * 2016-11-01 2021-12-29 F. Hoffmann-La Roche AG Bicyclic heteroaryl derivatives
WO2019121434A1 (en) * 2017-12-18 2019-06-27 F. Hoffmann-La Roche Ag Triazolo-azepine derivatives
CN111417636B (zh) * 2018-01-22 2023-09-26 豪夫迈·罗氏有限公司 三唑并-氮杂䓬衍生物
TWI841592B (zh) 2018-09-03 2024-05-11 瑞士商赫孚孟拉羅股份公司 雙環雜芳基衍生物
LT3894411T (lt) * 2018-12-13 2024-08-26 F. Hoffmann-La Roche Ag 7-fenoksi-n-(3-azabiciklo[3.2.1]oktan-8-il)-6,7-dihidro-5h-pirolo [1,2-b][1,2,4]triazol-2-amino dariniai ir susiję junginiai kaip gama sekretazės moduliatoriai alzheimerio ligai gydyti
US12275709B2 (en) 2018-12-27 2025-04-15 Hoffmann-La Roche Inc. Process for the preparation of exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate
NZ780966A (en) 2019-04-18 2026-02-27 Univ Johns Hopkins Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
IL301817A (en) 2020-10-13 2023-06-01 Univ Johns Hopkins Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003068776A1 (ja) * 2002-02-15 2005-06-02 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
AU2009216851B2 (en) * 2008-02-22 2013-11-07 F. Hoffmann-La Roche Ag Modulators for amyloid beta
WO2009128669A2 (ko) * 2008-04-16 2009-10-22 엘지이노텍주식회사 발광 소자 및 그 제조방법
AU2009312856A1 (en) * 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
TWI461425B (zh) * 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
CA2755467A1 (en) * 2009-05-07 2010-12-23 Janssen Pharmaceuticals, Inc. Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
WO2010138901A1 (en) * 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
EP2491524A4 (en) * 2009-10-23 2014-10-01 Apriva Llc SYSTEM AND DEVICE FOR CONSOLIDATING SIM, PERSONAL TOKEN AND ASSOCIATED APPLICATIONS
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
JP6831372B2 (ja) 2015-09-09 2021-02-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 架橋ピペリジン誘導体

Also Published As

Publication number Publication date
US20180237432A1 (en) 2018-08-23
HK1251902A1 (zh) 2019-04-26
EP3347363A1 (en) 2018-07-18
CN107922437A (zh) 2018-04-17
TW201718601A (zh) 2017-06-01
AR105965A1 (es) 2017-11-29
EP3347363B1 (en) 2020-01-01
US10604517B2 (en) 2020-03-31
TWI716446B (zh) 2021-01-21
JP2018526410A (ja) 2018-09-13
CN107922437B (zh) 2021-12-10
WO2017042114A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
TWI716446B (zh) 橋聯哌啶衍生物
JP7111704B2 (ja) 二環式ヘテロアリール誘導体
US10899766B2 (en) Bridged piperidine derivatives
JP7566745B2 (ja) アルツハイマー病の処置のためのガンマ－セクレターゼモジュレーターとしての、７－フェノキシ－ｎ－（３－アザビシクロ［３．２．１］オクタン－８－イル）－６，７－ジヒドロ－５ｈ－ピロロ［１，２－ｂ］［１，２，４］トリアゾール－２－アミン誘導体及び関連化合物
US10647721B2 (en) Bicyclic heteroaryl derivatives
EP3475279B1 (en) Triazolopyridines as gamma-secretase modulators
JP7248671B2 (ja) トリアゾロ－アゼピン誘導体
CA3107593A1 (en) Bicyclic heteroaryl derivatives

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20180427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210128

R150 Certificate of patent or registration of utility model

Ref document number: 6831372

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250